HistoSonics IPO
HistoSonics develops non-invasive focused ultrasound technology for treating solid tumors, including liver cancer. The company's Edison platform uses histotripsy technology to mechanically destroy targeted tissue without thermal effects, representing a promising approach in medical device innovation.
What We Know
HistoSonics has raised venture funding and advanced its technology through clinical trials and regulatory processes. The company received FDA approval for its liver cancer treatment system, marking a significant milestone, but has not announced IPO plans. Medical device companies with innovative cancer treatments often attract strong investor interest when going public. However, HistoSonics has not provided any confirmed timeline or details about potential IPO plans as it continues to commercialize its technology.
Frequently Asked Questions
Has HistoSonics had an IPO?
No, HistoSonics has not had an IPO. The medical device company remains privately held and has not announced plans to go public.
When is the HistoSonics IPO date?
HistoSonics has not announced an IPO date or provided any timeline for going public. There are no confirmed details about IPO plans. Sign up for alerts to stay informed.
How can I buy HistoSonics stock?
You cannot currently buy HistoSonics stock as it is a private company. If it goes public, shares would be available through standard brokers. Sign up for alerts to stay informed.
Stay Updated on the HistoSonics IPO
Get real-time alerts when HistoSonics files for an IPO, prices shares, or begins trading.
Get IPO Alerts